

10/542579

JC17 Rec'd PCT/PTO 15 JUL 2005

"Express Mail" mailing label number	EV 3931 28597 US
Date of Deposit	15 July 2005
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
QUEEN THOMAS	Queen Thomas
Printed Name	Signature

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: Conner, et al.

For: SULFONAMIDE DERIVATIVES AS
PPAR MODULATORS

Docket No.: X-16180

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,


Soonhee Jang
Attorney for Applicant(s)
Registration No. 44,802
Phone: 317-651-3571

Eli Lilly and Company
Patent Division/SJ
P.O. Box 6288
Indianapolis, Indiana 46206-6288

15 July 2005

FORM PTO 1449 (modified)	Atty. Docket No. X-16180	Serial No.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant Conner, et al.	
	Filing Date	Group

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	6,518,290	February 11, 2003	Sierra	
	AB	6,306,854	October 23, 2001	Brown, et al.	
	AC	6,369,098	April 9, 2002	Pershad Singh, et al.	
	AD	6,248,781	June 19, 2001	Jeppesen, et al.	
	AE	5,089,514	February 18, 1992	Hulin	
	AF	5,306,726	April 26, 1994	Hulin	
	AG	5,994,554	November 30, 1999	Kliwer, et al.	
	AH	5,232,945	August 3, 1999	Hulin	
	AI	5,902,726	May 11, 1999	Kliwer, et al.	
	AJ	6,506,757	January 14, 2003	Tajima, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO 03/072099	Sept. 4, 2003	Eli Lilly and Company		
	BB	EP 1 167 357	Feb. 1, 2002	Sankyo Company, Ltd.		
	BC	WO 02/18355	March 7, 2002	Eli Lilly and Company		
	BD	WO 02/16332	February 28, 2002	Eli Lilly and Company		
	BE	WO 01/16120	March 8, 2001	Eli Lilly and Company		
	BF	WO 01/00566	January 4, 2001	The Institutes for Pharmaceutical		

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

				Discovery, LLC.	10/542579	
	BG	EP 1 216 980	June 26, 2002	Eisai Co., Ltd.		
	BH	EP 0 930 229	July 21, 1999	Japan Tobacco Inc.		
	BI	WO 97/28115	August 7, 1997	Merck & Co.		
	BJ	WO 97/31907	September 4, 1997	Glaxo Group Limited		
	BK	GB 2 359 082	August 15, 2001	Kotobuki Pharmaceutical Company Ltd.		
	BL	WO 02/100813	December 19, 2002	Eli Lilly and Company		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CA	Sato, et al., "Synthesis and evaluation of novel fluorinated sulotroban-related sulfonamide derivatives as thromboxane A2 receptor antagonists," <i>Eur. J. Med. Chem.</i> , 30, pgs. 403-414 (1995)	
	CB	Sato, et al., "Asymmetric Synthesis of the Sulfoxide Metabolite of On-579 By The Kagan Protocol," <i>Bioorganic and Medicinal Chemistry Letters</i> , Vol. 7 No. 19, pgs. 2451-2454 (1997)	
	CC	Shinozaki, et al., "Synthesis and thromboxane A2 antagonistic activity of indane derivatives," <i>Bioorganic and Medicinal Chemistry Letters</i> , Vol. 9, pgs 401-406 (1999)	
	CD	Sato, et al., "Synthesis and evaluation of novel sulfonamide derivatives as thromboxane A2 receptor antagonists I," <i>Eur. J. Med. Chem.</i> , Vol. 29, pgs. 185-190 (1994)	
	CE	Berlot, et al., "Preparation of a dansylated fibrates, a new fluorescent tool to study peroxisome proliferation. Effect on hepatic-derived cell lines," <i>Biochimie</i> , Vol. 79, pgs. 145-150 (1997)	
	CF	Liu, et al., "Identification of a Series of PPAR γ / δ Dual Agonists Via Solid-Phase Parallel Synthesis," <i>Bioorganic and Medicinal Chemistry Letters</i> , Vol. 11, pgs. 2959-2962 (2001)	
	CG	Sarges, et al., "Glucose Transport-Enhancing and Hypoglycemic Activity of 2-Methyl-2-phenoxy-3-phenylpropanoic Acids," <i>J. Med. Chem.</i> , Vol. 39, No. 24, pgs. 4783-4803 (November 22, 1996)	
	CH	Cobb, et al., "N-(2-Benzoylphenyl)-L-tyrosine PPAR Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent," <i>J. Med. Chem.</i> , Vol. 41, No. 25, pgs. 5055-5069 (December 3, 1998)	
	CI	Bright, et al., "Competitive particle concentration fluorescence immunoassays for measuring anti-diabetic drug levels in mouse plasma," <i>Journal of Immunological Methods</i> , Vol. 207, No. 1, pgs. 23-31 (August 2, 1997)	
	CJ	Brooks, et al., "Design and Synthesis of 2-Methyl-2-[4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy]propionic Acids: A New Class of Dual PPAR Agonists," <i>J. Med.</i>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

		Chem., Vol. 44, No. 13, pgs. 2061-2064 (June 21, 2001)	10/542579
	CK	Shinkai, et al., "Isoxazolidine-3,5-dione and Noncyclic 1,3-Dicarbonyl Compounds as Hypoglycemic Agents," J. Med. Chem., Vol. 41, No. 11, pgs. 1927-1933 (May 21, 1998)	
	CL	Murugesan, et al., "Biphenylsulfonamide Endohelin Receptor Antagonists. 2. Discovery of 4'-Oxazolyl biphenylsulfonamides as a New Class of Potent, Highly Selective ET _A Antagonists," J. Med. Chem., Vol. 43, No. 16, pgs. 3111-3117 (August 10, 2000)	
	CM	Malamas, et al., "Azole Phenoxy Hydroxyureas as Selective and Orally Active Inhibitors of 5-Lipoxygenase," J. Med. Chem., Vol. 39, No. 1, pgs. 237-245 (January 5, 1996)	
	CN	Meguro, et al., "Studies on Antidiabetic Agents. VIII. Synthesis and Hypoglycemic Activity of 4-Oxazoleacetic Acid Derivatives," Chemical & Pharmaceutical Bulletin, Vol. 34, No. 7, pgs. 2840-2851 (1986)	
	CO	Xu, Yanping, et al., "Design and Synthesis of α -Aryloxy- α -methylhydrocinnamic Acids: A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/γ Agonists," J. Med. Chem., Vol. 47, No. 10, pgs. 2422-2425 (2004)	

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of

document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.